12:00 AM
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tradjenta: Phase III data

A double-blind, international Phase III trial of 235 Type II diabetes with moderate to severe renal impairment, defined as an estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73 m2, showed that once-daily 5 mg oral linagliptin met the primary endpoint of reducing mean HbA1c from baseline to week 12 vs. placebo...

Read the full 233 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >